FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Natco Pharma's Free Cash Flow for the
three
months ended in Mar. 2026 was ₹0 Mil. Natco Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹7,391 Mil. Therefore, Natco Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Natco Pharma's FCF Margin % or its related term are showing as below:
NSE:NATCOPHARM'
s FCF Margin % Range Over the Past 10 Years
Min: -10.3 Med: 6.68 Max: 33.77
Current: 33.77
During the past 13 years, the highest FCF Margin % of Natco Pharma was 33.77%. The lowest was -10.30%. And the median was 6.68%.
NSE:NATCOPHARM's FCF Margin % is ranked better than 97.28% of 956
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs NSE:NATCOPHARM: 33.77
Natco Pharma FCF Margin % Related Terms
Natco Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Natco Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NATCOPHARM vs ZTS, UTHR: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natco Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Natco Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natco Pharma (NSE:NATCOPHARM) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Natco Pharma and its competitors. According to the industry distribution chart, Natco Pharma ranks #26 out of 956 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Natco Pharma's FCF Margin % too high?
Natco Pharma's current FCF Margin % is 0.00%. Based on the distribution chart, Natco Pharma ranks #26 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Natco Pharma ranks #26 out of 956 companies for FCF Margin %. This places Natco Pharma in the top 3% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Natco Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natco Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹938.21, compared to a current price of ₹931.30 — trading 0.7% below its estimated fair value. The current FCF Margin % is 0.00%. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued.
The current stock price of ₹931.30 is trading 0.7% below its estimated GF Value™ of ₹938.21.
GuruFocus considers Natco Pharma to be Fairly Valued.
Key valuation signals for NSE:NATCOPHARM:
FCF Margin %: 0.00%
GF Value™: ₹938.21 vs. price of ₹931.30 (0.7% below fair value)
No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score
Get the complete analysis for NSE:NATCOPHARM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NATCOPHARM has been successfully added to your 
